Cleara is a biopharmaceutical R&D company dedicated to discovery and development of therapies against cancer and chronic diseases through selective elimination of subtypes of cellular senescence. Through detailed understanding of the molecular and biological pathways that underlie these individual pathological phenotypes, we set up disruptive, innovative and proprietary platform technology to design and optimize (peptide-based) therapeutics that exploit their weak spots for safe and selective clearance. Cleara’s lead FOXO4 program is focused on generation of disruptive and proprietary technology against “scarred” cellular senescence for treatment of metastatic, mutant-p53 cancer. Senescent cells are associated with a range of chronic diseases and cancer progression. However, Cleara acknowledges that there are different kinds of senescence. We do not focus on “magic bullets” to kill all senescent cells but develop specific and safe compounds against unique subtypes. Cleara’s goal is to progress these into clinical development with the intent of precision medicine against specific diseases with clear niche-directed anti-senescence lead candidates, with associated biomarkers, around its FOXO4-based D-amino acid pipeline.